Chemotherapeutic options in lung cancer

Cancer

Volumn 83, Issue 8 SUPPL., 1998, Pages 1740-1750

  Bunn Jr , Paul A ^a   Soriano, Ariel F ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; RETINOL; SELENIUM; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADVERTIZING; CANCER CHEMOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CONFERENCE PAPER; HEALTH EDUCATION; LUNG CANCER; METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 3543138803     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19981015)83:8+<1740::aid-cncr16>3.0.co;2-u     Document Type: Conference Paper

References (34)

1. Parker SL, Tong T, Belden S, Wingo PA. Cancer statistics, 1997. Cancer J Clin 1997;47:5-27.
2. DeVita VT, Hellman S, Rosenberg SA. Cancer. Principles and Practice of Oncology. 5th ed. 1997.
3. Fraumeni JF Jr., et al. Lung and pleura. In: Schottenfeld D, Fraumeni JF Jr., editors. Cancer epidemiology and prevention. Philadelphia: WB Saunders, 1982: 564.
4. Cook R, Miller Y, Bunn P. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment. Curr Probl Cancer 1993;17:69-144.
5. Pignon JP, Arriagada R, Ihde CE, et al. A meta-analysis of thoracic irradiation for small cell lung cancer. N Engl J Med 1992;327:1618-24.
6. Turrisi A, Kim K, Sause W, Komaki R, Wagner R, Aisner S, et al. Observations after 5 year follow-up of Intergroup Trial 0096:4 cycles of cisplatin (P) etoposide (E) and concurrent 45 Gy thoracic radiotherapy (TRT) given in a daily (QD) or twicedaily fractions followed by 25Gy PCI. Survival differences and patterns of failure. Proc Am Soc Clin Oncol 1998;17:457A.
7. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer: A Phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91.
8. Fukuoka M, Furese K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991;83:855-61.
9. Bunn PA, Cullen M, Fukuola M, et al. Chemotherapy in small cell lung cancer. A consensus report of the International Association for the Study of Lung Cancer Workshop. Lung Cancer 1989;5:127-34.
10. Harper PG, Underhill C, Ruiz de Elvira MC, et al. A randomized study of oral etoposide versus combination chemotherapy in poor prognosis smaall cell lung cancer. J Clin Oncol 1996;14:1750.
11. Bunn PA Jr. Future directions in therapeutic approaches for small cell lung cancer. Semin Oncol 1996;23(6 Suppl 16):136-8.
12. Arrigada R, Auperin A, Pignon JP, et al. Prophylactic cranial irradiation overview (PCIO) in patients with small cell lung cancer (SCLC) in complete remission (CR). Proc Am Soc Clin Oncol 1998;17:457A.
13. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
14. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of Stage I lung cancer with high dose vitamin A. J Clin Oncol 1993;11(7):1216-22.
15. Bunn PA Jr. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin Oncol 1994;21(3 Suppl 6):49-59.
16. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
17. Martini N, Kris M, Flehinger B, et al. Preoperative chemotherapy for Stage IIIA (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55:1365-74.
18. Burkes R, Ginsberg, Shepherd F, et al. Induction chemotherapy with mitomycin C, vindesine and cisplatin for Stage III unresectable non-small cell lung cancer: results of the Toronto Phase II trial. J Clin Oncol 1992;10:580-6.
19. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of Cancer and Leukemia Group B protocol 8935: multiinstitutional Phase II trimodality trail for Stage IIIA (N2) NSCLC. J Thorac Cardiovasc Surg 1995;109:473-85.
20. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330:153-8.
21. Roth JAB, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable Stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1992;86:673-80.
22. Greco FA, Hainsworth JD. Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung. Oncology 1997;11:27-36.
23. Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605. Report and analysis of recurrent disease data base. Cancer 1993; 72:1184-91.
24. Schaake-Koning C, Van Den Bogert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N Engl J Med 1992;326:524-30.
25. Dillman RO, Seagren SL, Herndon J, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small cell lung cancer. N Engl J Med 1990;323:940-5.
26. Dillman RO, Herndin J, Seagren SL, et al. Improved survival in Stage III non-small cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
27. Le Chevalier T, Arrigada R, Quiox E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
28. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable NSCLC. A meta-analysis. Ann Int Med 1996;125(9):723-9.
29. Minna JD, Pass HI, Glatstein E, Ihde DI. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology, ed 3. Philadelphia: JB Lippincott, 1989: 591.
30. Ihde DC, Minna JD. Non-small cell lung cancer. II. Treatment. Curr Prob Cancer 1991;15:105-54.
31. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multi-center randomized trial. J Clin Oncol 1988;6:663-41.
32. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;5:1087-100.
33. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial [abstract]. Proc ASCO 1996;15:382.
34. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990;8:1301-9.